Projects
1. HPV testing and the long term risk of cervical premalignant disease
M. Kocken1, J.A. Louwers1, A. Zaal1, J. Berkhof1 P.J.F. Snijders1, R.H.M. Verheijen2, W.A. ter
Harmsel3 ,Th.J.M Helmerhorst4 ,C.J.L.M. Meijer1
1VU University Medical Center, Amsterdam, 2) University Medical Center Utrecht, Utrecht, 3) Reinier
de Graaf groep, Delft/Voorb urg, 4) Erasmus University Medical Center, Rotterdam (HumaVac)
2. Human papillomavirus infection and cervical cancer: epidemiology and screening
D. Rijkaard, D.A.M. Heideman, F.J. van Kemenade, B. Hesselink, L. Rozendaal, H. Berkhof, PJF
Snijders, CJLM Meijer
Dept. of Pathology, VU University Medical Center, Amsterdam (ZON-MW 22000147 and 6200.0013;
SRP)
3. Stratifying high-risk HPV positive women for risk of CIN 3 and cervical carcinoma by HPV
transcript analysis
M. Dijkstra, D.A.M. Heideman, R.H.M. Verheijen, C.J.L.M. Meijer, P.J.F. Snijders
Dept. of Pathology, VU University Medical Center, Amsterdam (KWF 2006-3570)
4. A subset of chemotherapy-refractory diffuse large B-cell lymphomas is characterized by
constitutive upstream activation of the intrinsic apoptosis pathway
N. Michitake1,2, S.A.G.M. Cillessen1, J.J. Oudejans1,3, C.J.L.M. Meijer1
Depts. of 1Pathology, VU University Medical Center, Amsterdam. 2Central Research Laboratories,
Sysmex Corporation, Kobe, Japan. 3Dept of Pathology, Diakonessenhuis, Utrecht (Sysmex)
5. Clinical and biological relevance of focal aberrations in colorectal cancer
O. Krijgsman, B. Carvalho, B. Ylstra, R. Steenbergen, G.A. Meijer
Dept. of Pathology, VU University Medical Center, Amsterdam (CCA/V-ICI)
6. Early detection of coloractal cancer by faeces derived miRNA testing
L.M. Timmer, B. Diosdado, E. Cuppen, C. Mulder, R. Steenbergen, G. Meijer
Dept. of Pathology, VU University Medical Center, Amsterdam (KWF2009-4276)
7. Epidemiology and screening for nasopharyngeal carcinoma
S Hutajulu1, J Fachiroh1, M Adham2, DK Paramita1, N Ng1, SM Haryana1, P.Brennan3, IB Tan4
AE.Greijer5, , and JM Middeldorp5
1Gadjah Mada Univ Med School, Dept. ENT, Yogyakarta, and 2 Dept. ENT, Dr. Cipto Mungunkusumo
Hospital, Jakarta, Indonesia, 3WHO-IARC, Dept. Gen and Environ Epidem, Lyon, France, 4Netherl
Cancer Instit, Dept. ENT Surgery, and 5VU University medical center, Dept. Pathol, Amsterdam
(KWF-IN2004-17; KWF-IN 2006-21, WHO-IARC, ASI/B7-301/98/679-034, Nuffic CF4663/2008)
8. Epstein Barr Virus Activation and cytolytic antiviral therapy in nasopharyngeal carcinoma
patients
AE.Greijer, SAMW.Verkuijlen, H.Juwana, M.Wildeman1, J.Kurnianda2, IB Tan1 and JM.Middeldorp
Dept. ENT, Netherlands Cancer Institute, Dept. Medical Oncology, Dr.Sardjito hospital, Gadjah Mada
university, Yogyakarta, Indonesia and Dept. Pathology, VU University medical center, Amsterdam
(KWF-IN, ZonMW)
9. Epstein Barr virus elimination by small molecules as treatment for EBV-driven lymphomas and
carcinomas
AE Greijer1, I de Esch2, R Leurs2, JM Middeldorp1
1Department of Pathology, VU University Medical Centre 2Division of Medical Chemistry FEW,
Chemistry, VU, Amsterdam, The Netherlands (KWF / STW)
10. Epstein-Barr virus (EBV) and African Burkitt Lymphoma
JM Middeldorp1, SA Verkuijlen1, H Juwana1, AE Greijer1, CJLM Meijer1, J Orem2, M.Allday3,
E.Piriou4 and E.Weiderpass5.
1Dept. Pathology, VU University medical center, 2Dept. Oncology, Makarere University Hospital,
Kampala, Uganda, 3 Dept. Tumor virology, Imperial College of London, UK, 4Kenya Medical Research
Institute, Kisumu, Kenya and 5Dept. Epidemiology Karolinska Institute, Stockholm, Sweden (Funding:
project EBV-Burkitt KI-Nordic Cancer Registry)
11. Epstein-Barr virus markers and chronic disease
H.Juwana, L.Peferoen, L.Lodder, AE.Greijer, S.Amor and JM Middeldorp
VU University medical center, Dept. Pathology, Amsterdam. (NCI RTI, Vumc student travel grant, MS
foundation)
12. The Role of Human papillomavirus and non-cervical cancer
R.D.M. Steenbergen, D.A.M. Heideman, M.C.G. Bleeker, S. Wilting, C.J.L.M. Meijer, P.J.F. Snijders
Dept. of Pathology, VU University Medical Center, Amsterdam (KWF)
13. Human papillomavirus infection and cervical cancer: epidemiology, screening and clinical
implementation
C.J.L.M. Meijer, D.A.M. Heideman, F.J. van Kemenade D. Rijkaart, M. Dijkstra, M. Gök, V. Coupé, B.
Hesselink, R.D.M. Steenbergen, R. Pol, N. Fransen-Daalmeijer, M. Lettink, D. Buma, D. Boon, M.
Boogaart, S. Gierveld, F. Topal, M. Verkuyten, R.E. van Andel, L. Rozendaal , H. Berkhof, P.J.F.
Snijders
Dept. of Pathology, VU University Medical Center, Amsterdam (KWF VU 2006-3570/ZON-MW
120610010/RIVM V210021-01-HPV/IKA/SO)
14. Immunogenicity and efficacy of HPV 16/18 l1/AS04 vaccine (HPV-015 prophylactic vaccination
study)
J.A. Louwers1, M. Kocken1, A. Zaal1, J. Berkhof1 P.J.F. Snijders1, R.H.M. Verheijen2, W.A. ter
Harmsel3 ,Th.J.M Helmerhorst4 ,C.J.L.M. Meijer1,
1) VU University Medical Center, Amsterdam, 2) University Medical Center Utrecht, Utrecht, 3)
Reinier de Graaf groep, Delft/Voorburg, 4) Erasmus University Medical Center, Rotterdam (GSK
Biologicals, Rixensart)
15. Lung cancer: guiding diagnosis and treatment response with biomarkers
D.A.M. Heideman1, P.E. Postmus2, E.F. Smit2, G.A. Meijer, P.J.F. Snijders1, F.B.J.M.
Thunnissen1Dept. of Pathology1 and Pulmonology2, VU University Medical Center, Amsterdam (LPT
grant / Educational grant AZ)
16. Simplified monitoring post-treatment CIN 2/3 women by molecular testing for hrHPV and
methylationmarkers (SiMoNaTh)
M. Uijterwaal, M. Kocken1, R.D.M. Steenbergen1, J. Berkhof1 P.J.F. Snijders1, R.H.M. Verheijen2, P.
Graziosi3, C.J.L.M. Meijer1,Th.J.M Helmerhorst41) VU University Medical Center, Amsterdam, 2)
University Medical Center Utrecht, Utrecht, 3) St. Antonius Hospital,Nieuwegein, 4) Erasmus
University Medical Center, Rotterdam (KWF2009-4413)
17. EBV immunopathogenesis: the role of LMP1 containing exosomes
DM.Pegtel, M.van Eijndhoven, E.Hooijberg, E.Bloemena and JM.Middeldorp
Dept. of Pathology, VU University Medical Center, Amsterdam (KWF, EU-Epilymph)
18. Immune responses to EBV tumour-associated proteins in nasopharyngeal carcinoma
D. Paramita, J.M. Middeldorp
Dept. of Pathology, VU University Medical Center, Amsterdam (KWF-IN)
19. Role of soluble BARF1 oncoprotein in Epstein-Barr virus driven carcinogenesis and its
functional inhibition by antibodies
E.K. Hoebe, E. Hopmans, A.E. Greijer, J.M. Middeldorp
Dept. of Pathology, VU University Medical Center Amsterdam (KWF)
20. Targeting the extracellular domains of EBV-encoded tumor-associated latency proteins
J.M. Middeldorp
Dept. of Pathology, VU University Medical Center, Amsterdam (Industry)
21. In situ targeting and modulation of dendritic cells for immunotherapy: identification of DC
targeting motifs
D. Oosterhoff1, R. van de Ven2, J.J. Lindenberg1, B. Hangalapura1, S.M. Lougheed1, P. van den Tol3,
D.T. Curiel4, V.W. van Beusechem1, W.R. Gerritsen1, A.J.M. van den Eertwegh1, R.J. Scheper2, T.D.
de Gruijl1
Depts. of 1Medical Oncology, 2 Pathology, and 3Surgical Oncology, VU University Medical Center,
Amsterdam and Division of Human Gene Therapy, UAB, Birmingham, Alabama (NWO VIDI)
22. In situ targeting and modulation of dendritic cells for immunotherapy: reversal of suppression
J.J. Lindenberg1, D. Oosterhoff1, H. van Cruijsen1, S.M. Lougheed1, V.W. van Beusechem1, W.R.
Gerritsen1, A.J.M. van den Eertwegh1, R.J. Scheper2, T.D. de Gruijl1
Depts. of 1Medical Oncology, 2Pathology, VU University Medical Center, Amsterdam (NWO VIDI)
23. A human, in vitro, full-thickness tissue-engineered skin model to investigate hypertrophic scar
formation
L. van den Broek1, T. Waaijman, M. Breetveld1, R.J. Scheper2, F. Niessen3, S.Gibbs1
Depts. 1Dermatology / 2Pathology / Plastic Surgery3, VU University Medical Centre
24. A prediction model for the development of rheumatoid arthritis in anti-CCP and/or IgM
rheumatoid factor positive arthralgia patients
D. van Schaardenburg1, 2, W.H. Bos 1, C.L. Verweij1, D. Hamann4, M. Boers5, B.A.C. Dijkmans1, 2
Depts. of rheumatology1, Jan van Breemen Institute, rheumatology2, VUMC, rheumatology3, AMC,
Sanquin Research4 and clinical epidemiology5, VUMC (Reumafonds)
25. ABC transporters and drug resistance – SRP Monoclonalen
RJ Scheper, GL Scheffer, TD de Gruijl&, J de Groot, W. Bierman* and G. Jansen*
Depts. of Pathology, Medical Oncology & and Internal Medicine*, VU University Medical Center
26. Autologous tissue-engineered skin for healing chronic wounds
E.M. de Boer1,4, H.M. van den Hoogenband4, C. van Montfrans1, CS. Blok1,4, R. Lensen4, R.J.
Scheper2,4, S.Gibbs1,4.
Departments of 1Dermatology and 2Pathology, VU Medical Centre, 4A-SKIN (A-Skin, AGIS)
27. Dendritic cell-targeted in vivo tumor vaccination: towards optimised prime-boost protocols
B.N. Hangalapura1, D. Oosterhoff1, Y. van Kooyk2, J. van Moorselaar3, E. Hooijberg4, V.W. van
Beusechem1, W.R. Gerritsen1, A.J.M. van den Eertwegh1, R.J. Scheper4, T.D. de Gruijl1
Depts. of 1Medical Oncology, 2Molecular Cell Biology and Immunology, 3Urology, and 4Pathology,
VU University Medical Center, Amsterdam (KWF-VU / Stichting Avanti/STR)
28. Development of a 'chemokine/angiogenic cocktail' for facilitating closure of burns and
improving scar quality
K. Kroeze1, S.C. Sampat1, M. Breetveld1, R.J. Scheper2, S.Gibbs1
Depts. 1Dermatology / 2Pathology, VU University Medical Centre (Nederlandse Brandwonden
Stichting)
29. Development of tissue engineered, autologous human skin for studying sensitization and
Immuno-Vaccination Approaches
K. Ouwehand1, S.W. Spiekstra1, B.M.E. von Blomberg2, T. Rustemeyer1, R.J. Scheper2, T.J. De
Gruijl2, S. Gibbs1
Departments of 1Dermatology and 2Pathology, VU University Medical Center (V-ICI)
30. Development of tissue-engineered full-skin substitutes for use in wound healing and industrial
screening
M. Breetveld1, T. Waaijman1, E. Middelkoop3, R.J. Scheper2, S. Gibbs1.
Depts. 1Dermatology / 2Pathology, VU Medical Centre, 3Association of Dutch Burns centres (dpte /
Zon-Mw / NBS)
31. Enteroviral infections in children
S. de Crom 1, Dr. Ch. Obihara 1, M. Peeters 2, S.A. Morré 3 , A. M. van Furth 4
1Dept. of Pediatrics, St. Elisabeth Ziekenhuis, Tilburg; 2 Dept. of Medical Microbiology , St. Elisabeth
Ziekenhuis, Tilburg; 3Dept. of Immunogenetica, VUmc, Amsterdam; 4Dept of Pediatric Infectious
Diseases, Immunology, and Rheumatology, VUmc, Amsterdam
32. Immunoprofiling in chronic inflammatory disease: coeliac disease
M.W.J. Schreurs1, W.H.M. Verbeek2, I.M.W. van Hoogstraten1, G.J. Tack2, C.J.J. Mulder2, B.M.E. von
Blomberg1
Depts. of 1Pathology, 2Gastroenterology, VU University Medical Center
33. Immunoprofiling in chronic inflammatory disease: contact allergy
I.M.W. van Hoogstraten1, J. Muris2, C.J. Cleverlaan2, J. Rezende2, T. Rustemeyer3, A.J. Feilzer2,
M.W.J. Schreurs1, R.J. Scheper1, B.M.E. von Blomberg1
Depts. of 1Pathology and 3Dermatology, VU University Medical Center , Dept. of 2Dental Materials
Science, ACTA, Amsterdam
34. Molecular targeting of intracellular proteins in cancer
KBJ Scholten1, TD de Gruijl2, GA Meijer1, GAMS van Dongen2 and E Hooijberg1
Departments of 1Pathology and 2Medical Oncology, VU University Medical Center (CCA)
35. Natural killer (T) effector cells in immunity
M. Moreno1,2, H.J. van der Vliet3, S von Mensdorff-Pouilly2, R.H.M. Verheijen2, A.J.M. van den
Eertwegh3, R.J. Scheper1, B.M.E. von Blomberg1, H.J. Bontkes1,4
Depts. of, 1Pathology and 2Obstetrics and Gynaecology, 3Medical Oncology and 4Hematology, VU
University Medical Center (KWF)
36. Novel in vitro assays for detection of sensitizers: Sens-it-iv
J. Reinders1, G. dos Santos1, S.W. Spiekstra1, B.M.E. von Blomberg2, R.J. Scheper2, T. Rustemeyer1,
S. Gibbs1.
Departments of 1Dermatology and 2Pathology, VU University Medical Centre (EU framework 6
project Sens-it-iv)
37. On the role of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis
A.M. Trujillo1, J.G.I. van Rietschoten2, T.C.G. Timmer1, T.W.J. Huizinga3, P. Tak4, M. Marsal5,
T.C.T.M. van der Pouw Kraan1 , B.A.C. Dijkmans6, C.L. Verweij1,6
1Dept. of Pathology, 2Molecular Cell Biology and Immunology, and 6Rheumatology, VU University
Medical Center, 3Dept. Clinical Immunology and Rheumatology, Academic Medical Center,
Amsterdam. 4Dept. Rheumatology, LUMC, Leiden, The Netherlands, 5Hospital Vall d'Hebron,
Barcelona, Spain (Dutch Arthritis Foundation, V-ICI, CMSB, IOP-SENTER genomics, EU-EuroRA MarieCurie)
38. On the role of the myofibroblast/like synoviocyte in angiogenesis in rheumatoid arthritis
M. Blits, C.L. Verweij
Dept of Pathology, VU University Medical Center, Amsterdam
39. Predicting T-cell lymphoma development in refractory coeliac disease patients by profiling of
apoptosis pathways in intestinal T-lymphocytes
J.M. van de Water1, C.J.L.M. Meijer2, Nathalie J Hijmering2, M. von Blomberg2, MWJ Schreurs2, J.J.
Oudejans1,3, C.J.J. Mulder1, S.A.G.M. Cillessen2
Depts. of 1Gastroenterology, 2Pathology, VU University Medical Center, Amsterdam. 3Dept of
Pathology, Diakonessenhuis, Utrecht (CCA 2007-2010)
40. SkinCare
K. Kroeze1, M. Obdeijn1, E.M. de Boer1,4, . van Montfrans1, CS. Blok1,3, R. Lensen3, R.J. Scheper2,3,
S.Gibbs1,3.
Departments of 1Dermatology and 2Pathology, VU University Medical Centre, 3A-SKIN (International
Innovation Programme by SenterNovem)
41. Study of MUC1 as a target for the immunotherapy of patients with breast and ovarian
carcinomas
M. Moreno1, R.J. Scheper2, H.J. Bontkes2, P. Kenemans1, R.H.M. Verheijen1, S. von MensdorffPouilly1
Depts. of 1Obstetrics and Gynaecology and 2Pathology VU University Medical Center
42. Towards adjuvant immunotherapy for squamous cell carcinoma
A. Turksma, J.J. Ruizendaal, C.J.L.M. Meijer, C.R. Leemans, E. Hooijberg
Dept. of Pathology, VU University Medical Center Amsterdam (KWF2007-3814)
43. Towards EBV tumor immunotherapy and vaccination
DK. Paramita, H.Juwana, E.Bloemena and JM.Middeldorp
VU University medical center, Dept. Pathology, Amsterdam (KWF-IN, SenterNovem-Eureka (IS062040/E3942); Industry)
44. Towards preventive medicine in Rheumatoid Arthritis: Alterations in innate immunity in the
preclinical phase of rheumatoid arthritis
L.G.M. van Baarsen1, W. Bos2, A.D. Adema1, T.C.T.M. van der Pouw Kraan3, G. Wolbink2,4, I. van der
Horst5, M. Schreurs1, M. Blomberg1, B. Crusius1, M. van der Wiel1,6,B.A.C. Dijkmans2,5, D. van
Schaardenburg2,5, C.L. Verweij1
1Dept. of Pathology and 3Dept. of Molecular Cell Biology, 5Dept. of Rheumatology, and 6Dept. of
Epidemiology, VU University Medical Center, 2Jan van Breemen Institute, 4Sanquin Research,
Amsterdam, The Netherlands (Autocure (EU), CMSB)
45. Prognostic monitoring of NPC treatment and realising a second center for NPC-expertise in
Indonesia
L. Adham, J.M. Middeldorp
Dept. of Pathology, VU University Medical Center, Amsterdam (KWF-IN)
46. FDG-PET for avoidance of futile direct laryngoscopies under general anasthesia with taking of
biopsies in patiens with suspicion on recurrent laryngeal carcinoma after radiotherapy
L. van der Putten, R. de Bree, C.R. Leemans, O. Hoekstra, E. Bloemena, I. van der Waal
Dept. Otolaryngology/Head and Neck Surger, Dept. of Pathology, VU University Medical Center,
Amsterdam (ZonMw)
47. Ultrasound guided fine needle aspiration cytology and sentinel node biopsy in the detection of
occult lymph node metastases of early oral and oropharyngeal cancer
G.B. Flach, R. de Bree, J Castelijns, I van der Waal, OS Hoekstra, E Bloemena
Dept. Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam (ZonMw)
48. Proteome profiling of human colon (tumor) tissue proximal fluids reveals candidate biomarkers
for colorectal cancer screening
Huub Kant1, Meike de Wit2, Sander R. Piersma1, Thang V. Pham1, Gerrit A. Meijer1, Remond J.A.
Fijneman2, Connie R. Jimenez1
1OncoProteomics Laboratory, Dept. of Medical Oncology, 2Tumor Profiling unit, Dept. of Pathology,
VU University Medical Center, Amsterdam, The Netherlands (Aegon International Scholarship in
Oncology, and by the VUmc-Cancer Center Amsterdam)
49. Proteome profiling of mouse colon tumor proximal fluids reveals candidate biomarkers for
colorectal cancer screening
Remond J.A. Fijneman1,2, Meike de Wit1, Maral Pourghiasian1,2, Sander Piersma2, Marc Warmoes2,
Pien M. van Diemen1, Chloe Piso1, Els C. Robanus-Maandag3, Ron Smits4, Riccardo Fodde4, Victor
W.M. van Hinsbergh2,5, Gerrit A. Meijer1 and Connie R. Jimenez2
1Dept. of Pathology, 2Dept. of Medical Oncology, 5Dept of Physiology, VU University Medical Center,
3Dept. of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands 4 Dept. of
Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, the Netherlands (Aegon
International Scholarship in Oncology, and by the VUmc-Cancer Center Amsterdam)
50. Sub-nuclear proteomics in human colorectal cancer: Identification of proteins enriched in the
nuclear matrix fraction and regulation in adenoma to carcinoma progression
Jakob Albrethsen1, Jaco C Knol1, Sander Piersma1, Thang V. Pham1, Meike de Wit2, Sandra
Mongera2, Beatriz Carvalho2, Henk MW Verheul1, Remond JA Fijneman2, Gerrit A Meijer2, and
Connie R Jimenez1*
1OncoProteomics Laboratory, Dept. Medical Oncology, 2Dept. Pathology (Tumor Profiling Unit), VU
University Medical Center, Amsterdam. The Netherlands (CCA)
51. Exploration of imaging potential of genomics candicates by cell-surface proteomics / Molecular
imaging of colorectal cancer
M. de Wit1, R.J.A Fijneman2, B. Carvalho1, S. Piersma3, C.R. Jimenez3 and G.A. Meijer1
1Dept. Pathology, VU University Medical Center, 2Dept. Medical Oncology, VU University Medical
Center, 3OncoProteomics Laboratory, VUmc-Cancer Center Amsterdam (Phillips / CCA)
52. Characterization and prognostication of salivary gland tumours
H Matse1, FM Raaphorst2, GA Meijer2, B Ylstra3, I van der Waal1, E Bloemena1,2
Depts of 1Oral and Maxillofacial Surgery/Oral Pathology, Academic Centre for Dentistry (ACTA),
2Pathology and 3Micro-array Unit, VU University Medical Center, Amsterdam Interuniversitaire
Onderzoeksschool Tandheelkunde (IOT)
53. EBV rapid test
H. Juwana, J.M. Middeldorp
Dept. of Pathology, VU University Medical Center, Amsterdam (Industry)
54. Evaluation of the immunostatus in coloncancer draining lymph nodes
T.D. de Gruijl, M.H.G.M. van der Pas, W.J.H.J. Meijerink, J.J. Lindenberg, D. Oosthoff, S.J.A.M.
Santegoeds, A.J.M. van den Eertwegh, R.J. Scheper, G.A. Meijer
Dept. of Surgery, Pathology and Oncology, VU University Medical Center, Amsterdam
55. Explorative biomarker studies towards patient centric therapy in rheumatoid arthritis
L.G.M. van Baarsen1, M. Blits1, T.C. Van der Pouw Kraan2, I. van der Horst3, A.E. Voskuyl3, M.T.
Nurmohamed4, M. Fero5, M. Schreurs1, M. Blomberg1, B. Crusius1, M. van der Wiel1,6,P.-P. Tak3 ,
B.A.C. Dijkmans4 and C.L. Verweij1,4
1Dept. Pathology, 2Dept. Molecular cell Biology, 3Dept. Rheumatology, 6Dept. of Epidemiology, VU
University medical center, 4Jan van Breemen Institute, Amsterdam, 5Stanford University, Palo Alto,
USA, 3Academic Medical Center, Amsterdam (V-ICI, Dutch Arthritis Foundation, AUTOCURE (EU) and
CMSB)
56. In vivo study to determine the efficacy of sentinel node mapping in patients with colon
carcinoma using near-infrared laparoscopy
M.H.G.M. van der Pas, D.L. van der Peet, O.S. Hoekstra, G.A.M.S. van Dongen, G.A. Meijer, S. Meijer,
M.A. Cuesta, W.J.H.J. Meijerink
Dept. of Surgery, VU University Medical Center, Amsterdam
57. Monitoring treatment efficacy and development of novel therapies in nasopharyngeal
carcinoma
M Adham1, DK.Paramita2, SM Haryana2, B.Hariwiyanto2, M.Wildeman3, AE.Greijer4, IB Tan3 and JM
Middeldorp4.
1Universitas Indonesia and Dr. Cipto Mungunkusumo Hospital, Dept. ENT, Jakarta, Indonesia, 2
Gadjah Mada University, Medical School, Dept. ENT and Tumor Biology, Yogyakarta, and
3Netherlands Cancer Institute, Dept. ENT Surgery, and 4VU University medical center, Dept.
Pathology, Amsterdam (KWF-IN 2006-21, KWF NKI-VU2008-4233)
58. Non-invasive diagnostic and prognostic markers in nasopharyngeal carcinoma
SAMW Verkuijlen, M.Adham, A.E. Greijer and JM Middeldorp
Dept. ENT, Universitas Indonesia, Jakarta, Indonesia and Dept. Pathology, VU University medical
center, Amsterdam (KWF-IN)
59. Personalized therapy in recurrent colorectal cancer
J.A.C.M. Goos, A.A. Geldof, R.J.A. Fijneman, G.A. Meijer, O.S. Hoekstra
Dept. of Nuclear Medicine & PET research and Pathology, VU University Medical Center Amsterdam
(CTMM)
60. Positron Emission Tomography (PET) for detection of histologic transformation of indolent
non-Hodgkin’s Lymphoma
M.J. Wondergem1, J.M. Zijlstra1, S.A.G.M. Cillessen2, J.J. Oudejans2, O.S. Hoekstra3, S. Zweegman1,
P.C. Huijgens1
Department of Hematology1, Pathology2, Nuclear medicine and PET research3 VU University
Medical Center (de Vilder Stichting)
61. Secondary prevention of gastrointestinal cancer
L. Bosch1, M. de Wit1, Q.J.M. Voorham1, S.T. van Turenhout2, F. Oort2, J.S. Terhaar2, S. Mongera1,
J.S. Bolijn1, L.Knols4, Fijneman R.J.A.1,3, B. Diosdado1, B. Carvalho1, M. van Engeland4 and G.A.
Meijer1
1Dept of Pathology, VU University Medical Center, Amsterdam, 2Dept of Gastroenterology, VU
University Medical Center, Amsterdam, 3Dept of Oncology, VU University Medical Center,
Amsterdam, 4Dept of Pathology, Maastricht University and University Hospital, Maastricht.
62. Tailoring of (immune-)therapy in R-CHOP refractory diffuse large B-cell lymphoma patients
S.A.G.M. Cillessen1, L.M.M. Moesbergen1, R. Kragten1, W. Vos1, G.J. Ossenkoppele2, J.J.
Oudejans1,3, C.J.L.M. Meijer1
Depts. of 1Clinical Pathology, 2Hematology, VU University Medical Center, Amsterdam. 3Dept of
Pathology, Diakonessenhuis, Utrecht (Dutch Cancer Society)
63. Tumor profiling of gastrointestinal (i.e. gastric & colorectal) cancer
C. Postma1, A.H. Hardebol1, J.C. Haan1, R.P.A. Brosens2, E. Belt2, M.Labots3, M. Tijssen1, S.
Mongera1, D. Israeli1, R.J.A. Fijneman1,3, B. Ylstra1, B. Diosdado1, B. Carvalho1, N.C.T. van
Grieken1, H. Verheul3, M.A. Cuesta2 and G.A. Meijer1
1Dept of Pathology, VU University Medical Center, Amsterdam, 2Dept of Surgery, VU University
Medical Center, Amsterdam, 3Dept of Oncology, VU University Medical Center, Amsterdam (Dutch
Cancer Society)
64. Early pathogenesis and intervention in Epstein-Barr virus (EBV) driven post-transplant
lymphoproliferative disease (PTLD) in stem cell (SCT) and solid organ transplant (SOT)
recipients
AE Greijer1, JJ Cornelissen2, CGM Kallenberg3, EAM Verschuuren2, L Verdonck4, SAWM
Verkuijlen1, J.M. Middeldorp
Depts. of 1Pathology, VUMC, Amsterdam, 2Hematology, ErasmusMC, Rotterdam, 3Internal
Medicine, UMCG, Groningen, 4Hematology, UMC Utrecht, The Netherlands (Dutch Cancer Society)
65. Optimizing strategies in dendritic cell vaccination in AML
W. van den Ancker1, T.M. Westers1, MM.van Luijn1, Jurjen M Ruben1, S. Santegoets2, A. Stam3, H.J.
Bontkes1, T.D. de Gruijl2, G.J. Ossenkoppele1, A.A. van de Loosdrecht1
Depts of 1Hematology, 2Medical Oncology and 3Pathology, VU University Medical Center (V-ICI)
66. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC
patients
Mariëlle I Gallegos Ruiz,1 Karijn Floor,1 José Ferreira,2 Katrien Grünberg,3 Frederik BJM Thunnissen,3
Jeroen AM Belien,3 Gerrit A Meijer,3 Godefridus J Peters,1 Egbert F Smit,4 José A Rodriguez1 and
Giuseppe Giaccone1
1Department of Medical Oncology, 2Department of Clinical Epidemiology and Biostatistics,
3Department of Pathology Department of Pathology, and 4Department of Pulmonary Diseases, VU
University Medical Center, Amsterdam, The Netherlands (KWF/NKB)
67. Dendritic and T cell functions in patients with metastatic hormone-refractory prostate cancer
treated with Prostate GVAX cancer immunotherapy and Ipilimumab
S.J.A.M. Santegoets2, A.J.M. van den Eertwegh1, A.G.M. Stam2, S.M. Lougheed1, H. Gall1, P.E.T.
Scholten2, B.M.E. von Blomberg2, E. Hooijberg2, K. Jooss4, N. Sacks4, K. Hege4, I. Lowy5, R.J.
Scheper2, W.R. Gerritsen1, T.D. de Gruijl1
Departments of 1Medical Oncology and 2Pathology of the VU University medical center, Amsterdam,
The Netherlands; 3Abramson Family Cancer Research Institute, University of Pennsylvania,
Philadelphia, PA; 4Cell Genesys Inc.,South San Francisco, CA; 5Medarex, Bloomsbury, NJ (Prostate
Cancer Foundation Research Award, Dutch Cancer Society)
68. Development of MUTZ-3 and novel AML-derived cell lines for DC-based allogeneic tumor
vaccination
S.J.A.M. Santegoets1,2, R. van de Ven1, H.J. Bontkes3, A.A. van de Loosdrecht3, A.J.M. van den
Eertwegh2, P.J.G.T.B. Wijnands5, A. Reurs5, M. Meerendonk5, J. Kaspers5, S. van Wetering5, A.M.
Kruisbeek5, T.D. de Gruijl4, and Rik J. Scheper1,5
Departments of 1Pathology, 2Medical Oncology, 3Hematology, 4Neurosurgery, and 5DC Prime BV,
VU University Medical Center, Amsterdam, The Netherlands (DC Prime, Biopartner FSG & Senter
Grant)
69. DNA copy number profiles associated with clinical outcome in advanced colorectal cancer
patients treated with folfiri and aliri regimens
Leticia G Leon,1,*, Elisa Giovannetti, 1,* Kees Smid,1 Axel R Hanauske,2 Bauke Ylstra,3 Gerrit A.
Meijer,3 Giuseppe Giaccone,4 Godefridus J Peters1
1Department of Medical Oncology, VU University Medical Center, Amsterdam; 2Eli Lilly & Co,
Indianapolis, IN, USA;3Department of Pathology, VU University Medical Center, Amsterdam;4Medical
Oncology Branch, National Cancer Institute, Bethesda, MD, USA
70. Human brain tumour studies: Radiosensitization & Genetics. Radiobiological studies in neurooncology: radiosensitization & genetics
P. Sminia1,K .A. van Nifterik1,3,4, J. van den Berg1, N. Ameziane2, L.J.A. Stalpers3, T.J.M. Hulsebos4,
S. Leenstra5, P. van der Valk6, M.V.M. Lafleur1, R. Mayer7; D. Brandsma8, M.J. van der Bent9, B.J.
Slotman1
Depts. 1Radiation Oncology, 2Oncogenetics, 6Pathology, VU University Medical Center, Depts.
3Radiation Oncology, 4Neurogenetics, Academic Medical Center, Amsterdam; 5Dept. Neurosurgery,
Sint Elisabeth Ziekenhuis, Tilburg; 7EBG MedAustron GmbH, Vienna, Austria; 8Dept Neurology,
Antoni van Leeuwenhoek Hospital, Amsterdam; 9Dept. Neuro-Oncology, Erasmus Medical Center,
Rotterdam, The Netherlands (Dutch Cancer Society)
71. Immunological studies supporting phase 1-3 active specific vaccination and chemoimmunotherapy trials in clinical cancer
S.J.A.M. Santegoets1, A.G. Stam2, H. van Cruijsen1, S.M. Lougheed1, P.E.T. Scholten2, B.M.E. von
Blomberg2, P.Pohlmann1, J. Buter1, H.M. Pinedo1, M. Suhoski3, C.H. June3, W.R. Gerritsen1, R.J.
Scheper2, A.J.M. van den Eertwegh1, T.D. de Gruijl1
Depts. of 1Medical Oncology and 2Pathology, VU University Medical Center, Amsterdam; 3Abramson
Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA (NWO Spinoza premie
H.M. Pinedo, KWF-VU)
72. Molecular basis of sensitivity/resistance for folate antagonist and other targeted drugs
G. Jansen1, J.W. van der Heijden1, R. Oerlemans1, W.F. Lems1, R.J. Scheper2, J. Cloos3, N.E. Franke3,
C. Lemos4, R. de Jonge5, G.J. Peters4, Y.G. Assaraf 6 and B.A.C. Dijkmans1
Depts. of 1Rheumatology, 2Pathology, 3Pediatric Oncology and 4Medical Oncology, VU University
Medical Center, Amsterdam, The Netherlands, 5 Dept. of Clinical Chemistry, Erasmus Medical Center,
Rotterdam, The Netherlands, 6Dept. of Biology, The Technion, Israel Institute of Technology, Haifa,
Israel
73. Multidrug resistance molecules in normal and malignant tissues
G.L. Scheffer, A.J.N. Schoonderwoerd, J de Groot, W Bierman, M van Agtmael, P. van der Valk, R.J.
Scheper
Dept. of Pathology, VU University Medical Center, Amsterdam (Sanbio, Alexis, Chemicon)
74. Proteasome inhibitor targeting of the (immuno)proteasome: effects on immune effector cells
and therapeutic consequences for cancer and chronic inflammatory diseases
S.E.Verbrugge1, T.D. De Gruijl2, R.J. Scheper3, B.A.C. Dijkmans1 and G. Jansen1
Depts. of 1Reumatology, 2Medical Oncology and 3Pathology, VU University Medical Center,
Amsterdam, The Netherlands (VUmc)
75. Radiation and targeted therapy of brain tumours
P. Sminia1,K .A. van Nifterik1,5,6, J. van den Berg1, N. Ameziane2, L.J.A. Stalpers5, T.J.M. Hulsebos6,
S. Leenstra7, P. van der Valk4, M.V.M. Lafleur1, R.D.M. Steenbergen3, B.J. Slotman1
Oncology, 2Oncogenetics, 3Molecular Pathology, 4Pathology, VU University Medical Center, Depts.
5Radiation Oncology, 6Neurogenetics, Academic Medical Center, Amsterdam; 7Dept. Neurosurgery,
St. Elisabeth Ziekenhuis, Tilburg (Dutch Cancer Society)
76. The identification of biomarkers/drugtargets specific for leukemic stem cells of Acute Myeloid
Leukemia and Chronic Myeloid Leukemia
L. Smit1, M. Terwijn1, A.R. Rutten1, F. Denkers1, J.J.W.M. Janssen1, S.J. Smeets2, V.W. van
Beusechem3, G.J. Ossenkoppele1, G.J. Schuurhuis1
Department of Hematology1, Microarray Facility, department of Pathology2, Department of Medical
Oncology3. VU University Medical Center, Amsterdam, The Netherlands
77. VEGFR Tyrosine Kinase Inhibition: effects on DC differentiation
H. Van Cruijsen1, D. Oosterhoff1, A.G.M. Stam2, A.J.M. van den Eertwegh1, E. Boven1, R.J. Scheper2,
G. Giaccone1, K. Hoekman1, T.D. de Gruijl1
Departments of 1Medical Oncology and 2Pathology, VU University Medical Center, Amsterdam, The
Netherlands (Stichting Medicina Interna and NWO VIDI 917.56.321)
78. Efficacy and toxicity of cerebral glioma treatment
I. Bosma1, M.J. Vos1, E. Sizoo1, M. de Groot1, T.J. Postma1, J.C. Reijneveld1,11, W.P. Vandertop2,11,
J.C. Baayen2, B.J. Slotman¬3, F. Lagerwaard3, J.Buter4 , M. Klein5, O.S. Hoekstra6, F. Barkhof7, E.
Sanchez7, P. van der Valk8, A.A.T.P. Brink8, M.A. Blankenstein9, J. Berkhof10, J.J. Heimans1
Department of 1Neurology, 2Neurosurgery, 3Radiotherapy, 4Medical Oncology, 5Medical
Psychology, 6 Nuclear medicine, 7Radiology, 8Pathology, 9Clinical Chemistry, and 10Clinical
Epidemiology and Biostatistics, VU University Medical Center, Department of 11Neurology and
12Neurosurgery, Academic Medical Center, Amsterdam
79. Acute myocardial infarction; hartfailure
M Begieneman1 1, P Krijnen2, H. Niessen2
1NFI, 2department of pathology VUmc (Nederlands Forensisch Instituut, Brandwondenstichting)
80. Woundhealing
M Begieneman1, B Drijber2, H. Niessen3, F vd Goot1
1NFI, 2GGD Amsterdam, 3Pathologie VUmc (Nederlands Forensisch Instituut, GGD Amsterdam)
81. Mechanism of venous graftfailure; Heart valve disease
M te Weeme1, A. Vonk2, H. Niessen3
1OLVG, 2Cardiosurgery VUmc, 3Pathology VUmc
82. Testing of human antibodies
83. K Kupreishvili, H. Niessen
Pathology (Genmab )
84. Stemcell therapy in the heart
A. van Dijk , B. Naaykens, H. Niessen
ICAR: 05-09; STW 09-11.; STW 09-13
85. EU 6th framework programm, acronym ADIT: Design of small molecule therapeutics for the
treatment of Alzheimer’s disease based on the discovery of innovative drug targets.
A. Rozemuller
Department of Pathology (EU)
86. The unfolded protein response in the pathogenic cascade of Alzheimer’s disease
JJM Hoozemans, A. Rozemuller
Department of Pathology (VENI ZonMW vernieuwingsimpuls: January 2007 – December 2010. )
87. Amyloid associated factors
R. Veerhuis1, A. Rozemuller2, Ph. Scheltens3, R. Blankenstein1
1Klinische chemie, 2Pathologie, 3Neurologie
88. Vascular factors in neurodegeneration
J. Geurts1, P. Scheltens2, A. Rozemuller1
1Pathologie, 2Neurologie
89. Blood-brain barrier alternations and capillary amyloid angiopathy
A. Carrano1, J. van Horssen2, A. Rozemuller1
1Pathologie, 2Molecular cell biology (St. Alzheimer onderzoek 2008-2010)
90. Early changes in Parkinson’s disease
A. Dijkstra1, A. Rozemuller2
1Anatomie en Neurowetenschappen 2Pathologie
91. Dynamics of protein folding
I. Idriss, A. Rozemuller, S. van der Vies
( NWO - EUROSCOPE 1-8-2007 / 1-1-2012)
92. Histopathology of the grey matter in MS
E-J Kooi, P. van der Valk , S. Amor MS, L. Boe,
Department of Pathology (Stichting vrienden MS research 02-498 (1-8-2007 / 31-7-2011))
93. Mitochondrial dysfunction in multiple sclerosis
M Witte , P. van der Valk, S. Amor
Department of Pathology (Stichting vrienden MS research, 05-581 )
94. Program grant 05-538c
W. Gerritsen, P. van der Valk, S. Amor
Department of Pathology ( Stichting vrienden MS research 05-538 (01-09-06 / 31-10-10))
95. Autoantobodies to neurofilaments in the pathogenesis of axonal damage and grey matter
pathology in MS
S. Amor. P. van der Valk
Department of Pathology (Stichting vrienden MS research 07-627 (01-09-07 / 31-08-11))
96. Rationale for the use of small molecule inhibitors that target epigenetic regulators in the
treatment of multiple sclerosis.
Claudia Alferink , P vd Elsen
(Dutch MS Research Foundation 2009-2010)
97. Identification of target kinases for drug therapy in Alzheimer disease
Jeroen Hoozemans, S. van der Vies, A. Rozemuller
(Stichting Alzheimer Onderzoek)
98. Decrease Colorectal Cancer Death
B. Carvalho, RJA Fijneman, B. Ylstra, O. Hoekstra, C. Jimenez, J. Beliën, G.A. Meijer,
CTMM (2008 – 2013)
99. Identification of small non-coding RNA’s.
B. Diosdado, G.A. Meijer
Department of Pathology (InteRNA)
100. Datamanagement in darmkanker
C. Parlayan, JAM Beliën, GA Meijer
Department of Pathology (Stichting Avanti)
101. Identification and regulation of tumor suppressors preventing oncogenic B-RAFE600associated melanoma
C. Homig, S. Douma, D. Peeper, W. Mooi
(KWF (15/8/2006-15/8/2010))
102. The anoikis suppressor TrkB as a target for novel anti-cancer agents
T. Geiger, T. Gallenne, A. Rosado, C.Desmet,D. Peeper, W. Mooi, others
(EU FP6 project: 1/1/2007-1/1/2010)